Base Year
Historical Year
Forecast Year
The Europe biosimilar market reached a value of almost USD 5,751.95 million in the year 2023. The biosimilar industry is further expected to grow at a CAGR of 25% between 2024 and 2032 to reach a value of almost USD 42,855.44 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The Europe biosimilar market is driven by the initiatives by the European Medicines Agency (EMA). The market within the region exhibits the most mature market in the world and continues to gain momentum. The industry is further anticipated to have rapid growth in the next five years as a number of major biologics are scheduled to lose patent protection within the region. Germany was the largest biosimilars market in Europe in the year 2020.
Biosimilars are referred to as the biotherapeutic products, which are similar to already licensed reference biologics, on the basis of quality, safety, and efficiency. These are manufactured and approved in alignment with the stringent laws of the European Medicines Agency (EMA). The Europe biosimilar market is divided on the basis of molecule into:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of manufacturing type, the industry is divided into:
On the basis of indication, the Europe biosimilar market is segregated into:
The report also covers the regional markets of biosimilar in Europe like Italy, Germany, France, the United Kingdom, Spain, and the rest of Europe.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The Europe biosimilar market is driven by the short marketing times as launching a biosimilar does not involve extensive marketing as the security and efficacy profile of their branded counterparts has already been established. The market is further aided as the product is less expensive as compared to their branded counterparts owing to no requirement for extensive research and testing, saving both money and time; thus, reducing overall costs. Many blockbuster biologics are anticipated to lose their patent protection in this decade. The expiration of patents and other intellectual property rights is projected to generate huge opportunities for biosimilar manufacturers, further aiding the industry growth in the region over the forecast period.
A significant amount of the European population is over the age of 65 years, accounting for about one-fifth of the total population within the region. This has led to a significant increase in the burden of lifestyle diseases in Europe. The rising prevalence of diseases like oncology, autoimmune diseases, and diabetes in Europe is also expected to impel the industry growth of biosimilars during the forecast period.
The report gives a detailed analysis of the following key players in the Europe biosimilar market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Molecule |
|
| Breakup by Manufacturing Type |
|
| Breakup by Indication |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Price Analysis |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
In 2023, the Europe biosimilar market attained a value of nearly USD 5,751.95 million.
In the forecast period of 2024-2032, the market in Europe is projected to grow at a CAGR of 25%.
By 2032, the market is estimated to reach a value of about USD 42,855.44 million.
The major market drivers include the rising prevalence of autoimmune diseases and diabetes, low costs of biosimilar, and rising geriatric population.
The key trends guiding the market are the expiry of various patents, short marketing times of biosimilars, and the increasing approvals of biosimilars by healthcare bodies.
The major countries in the Europe market are Italy, Germany, France, the United Kingdom, and Spain, among the rest of Europe.
The significant molecule segments of biosimilar considered in the market report are infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab, and follitropin alfa, among others.
The major indications considered in the market report are auto-immune diseases, blood disorders, diabetes, oncology, growth deficiency, and female infertility.
In-house manufacturing and contract manufacturing are the most significant manufacturing types in the industry.
The major players in the industry are Pfizer Inc., Celltrion Inc., Novartis AG, Merck Sharp & Dohme Corp., Eli Lilly and Company, and Samsung Bioepis, Accord-UK Ltd., among others.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share